logo
Plus   Neg
Share
Email

Argos To Terminate ADAPT Study; Plans To Explore Strategic Alternatives

Argos Therapeutics, Inc. (ARGS) reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastatic renal cell carcinoma. Based on the results, the company has decided to discontinue the trial.

Argos said it plans to explore a wide range of strategic alternatives that may include a potential merger or sale of the company, among other potential alternatives. The company has retained Stifel, Nicolaus & Company, Incorporated to serve as its financial advisor in the process.

Argos also reported that it does not expect to regain compliance with The Nasdaq Capital Market continued listing requirements by the April 24, 2018 deadline. As a result, Argos expects that its common stock will be delisted from The Nasdaq Capital Market and that trading in the company's common stock on The Nasdaq Capital Market will be suspended effective at the open of business on April 23, 2018.

Argos Therapeutics has filed an application to transfer trading and quotation of its common stock to the OTCQB Venture Market, operated by OTC Markets Group Inc., under its current trading symbol, ARGS, effective as of April 23, 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Kylie Cosmetics and Kylie Skin is set for a growth after the cosmetics company launched by Kylie Jenner in 2015 sold a major majority stake to beauty conglomerate Coty for $600 million. Jenner, who has been maintaining the full ownership of the company since its launch, sold 51 percent stake in Kylie... FedEx Corp. Chairman and CEO Fred Smith issued a challenge to the New York Times for publishing a "distorted and factually incorrect" story regarding corporate tax payments by the package delivery giant. The New York Times reported on Sunday that FedEx had made a major push for a reduction in corporate taxes when Donald Trump won the presidential election. A new study showed that foot traffic at Starbucks stores declined after the coffee giant changed to an 'open bathroom' policy. According to the study, store attendance per month at Starbuck stores declined 6.8 percent, relative to nearby restaurants and cafes, after the company made changes to its bathroom policy. In May 2018, Starbucks announced a new bathroom policy.
Follow RTT
>